Matyásová I, Rainetová P, Cástková J
Centre of Epidemiology and Microbiology, NRL for Enteroviruses, National Institute of Public Health, Prague, Czech Republic.
Cent Eur J Public Health. 2003 Dec;11 Suppl:S31-5.
Regular vaccination against poliomyelitis was started in 1960 with oral polio vaccine (OPV). Since 1992 a trivalent OPV has been administered in five doses within a nationwide vaccination campaign. The immunization coverage varies between 96.8% and 98.2% after 4 OPV doses, reaching 98.0% to 98.9% after the fifth dose. No case of indigenous poliomyelitis has been reported in the Czech Republic since the second half of 1960. In 2001, 3,230 sera were tested for the presence of antibodies against poliovirus of types 1, 2 and 3 using a virus neutralization microassay. The prevalence rates of antibodies vary between 96.0% and 100% for types 1 and 2 and between 95.1% and 100% for type 3, with the exception of the highest age group, in which the prevalence rates of antibodies against poliovirus of all three types are 92.2%.
1960年开始使用口服脊髓灰质炎疫苗(OPV)进行常规脊髓灰质炎疫苗接种。自1992年起,在全国范围内的疫苗接种活动中,三价OPV按五剂次接种。接种四剂OPV后的免疫覆盖率在96.8%至98.2%之间,第五剂接种后达到98.0%至98.9%。自1960年下半年以来,捷克共和国未报告本土脊髓灰质炎病例。2001年,使用病毒中和微量测定法对3230份血清进行了1型、2型和3型脊髓灰质炎病毒抗体检测。1型和2型抗体的流行率在96.0%至100%之间,3型在95.1%至100%之间,但最高年龄组除外,该组中所有三种类型脊髓灰质炎病毒抗体的流行率为92.2%。